21:06 , Nov 16, 2017 |  BC Innovations  |  Emerging Company Profile

YAP off, YAP on

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers....
22:54 , Sep 14, 2017 |  BC Innovations  |  Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other molecule...
20:55 , Jul 5, 2017 |  BioCentury  |  Finance

Cross-border cachet

Vivace Therapeutics Inc.’s investors are hoping to leverage the management team’s experience running a U.S.-China cancer company, but this time the goal is to retain more value by advancing the programs into the clinic. Vivace...
19:47 , Jul 5, 2017 |  BC Week In Review  |  Financial News

Vivace emerges from stealth with $25M series B round

Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode on June 28, saying it raised $25 million in a series B round led by new investor Cenova Capital. Also participating were new investor Sequoia...
13:24 , Jun 28, 2017 |  BC Extra  |  Financial News

Vivace out of stealth with $40M in two rounds

Cancer play Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode and announced a $25 million series B round led by new investor Cenova Capital. Also participating were new investor Sequoia Capital China and...
07:00 , Mar 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer MicroRNA-31 (miR-31); LATS large tumor suppressor homolog 2 (LATS2); protein phosphatase 2 regulatory subunit B a-isoform...